| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_478feb445d9f0fba59165e2d4af954bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_04a4ef58bb87725526fd4558fd9a864f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95c564097de19aae01c6674e6314d769 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-90 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-90 |
| filingDate |
1999-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f4ffd74b844ca79a0790f34e0f60319
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ff6f18276b61aee1b61a8abf554e5db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c7bdb200ad06bdbc2b5d733df66978b |
| publicationDate |
2000-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0025782-A1 |
| titleOfInvention |
Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists |
| abstract |
Novel dihydropyridinone and pyrrolinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016016238-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9932309-B2 |
| priorityDate |
1998-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |